You just read:

New Intarcia Study Evaluates Optimal Way to Switch from Daily Liraglutide Injections to ITCA 650 in Patients with Type 2 Diabetes

News provided by

Intarcia Therapeutics, Inc.

Sep 15, 2017, 11:26 ET